

# بسم الله الرحمن الرحيم





# شبكة المعلومات الجامعية

## التوثيق الالكتروني والميكروفيلم





# جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم


## قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



## يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار





# بعض الوثائق الأصلية تالفة







بالرسالة صفحات  
لم ترد بالأصل



**Usefulness of Carcinoembryonic Antigen (CEA) in  
Evaluating Response to Chemotherapy in Patients  
with Advanced Non-Small Cell Lung Cancer**

*Thesis*

*Submitted in Partial Fulfillment of Master Degree in  
Clinical Oncology and Nuclear Medicine*

*By*

***Alaa Naguib Mohammed Hassan***

*Under the Supervision of*

**Prof. Dr. Sherif Ahmed Abdelwahab**

*Professor of Clinical Oncology and Nuclear medicine  
Faculty of Medicine-Ain Shams University*

**Prof. Dr. Dina Ahmed Salem**

*Professor of Clinical Oncology and Nuclear Medicine  
Faculty of Medicine-Ain Shams University*

**Dr. Caroline Magued Elmaraghi**

*Lecturer of Oncology and Nuclear Medicine  
Faculty of Medicine-Ain Shams University*

*Faculty of Medicine  
Ain Shams University*

**2020**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا انك لا تعلم لنا  
إلا ما علمتنا إنك أنت  
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgment

*First and foremost, I feel always dependent to Allah, the most Beneficent and Merciful who gave me the strength to accomplish this work.*

*My deepest gratitude to my supervisor, Prof. Dr. Sherif Abd Elwahab, Professor of Oncology and Nuclear Medicine, Faculty of medicine –Ain Shams University, for his valuable guidance and expert supervision, in addition to his great deal of support and encouragement. I really have the honor to complete this work under his supervision.*

*I would like to express my great and deep appreciation and thanks to Prof. Dr. Dina Ahmed Salem, Professor of Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for her patience in reviewing the work and correcting it.*

*I must express my deepest thanks to Dr. Caroline Maqued Elmaraghi, Lecturer of Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University for guiding me throughout this work and for granting me much of her time. I greatly appreciate her efforts.*

*Thanks a lot to all my professors and colleagues for their considerable care and support.*

*Special thanks to My Mother, Husband And My Sisters for their continuous support.*

**Alaa Naguib**



# *List of Contents*

Title	Page No.
List of Tables .....	5
List of Figures .....	6
List of Abbreviations .....	7
Introduction .....	1
Aim of the Work.....	3
Review of Literature	
📖 Epidemiology .....	4
📖 Screening.....	8
📖 Risk Factors.....	10
📖 Diagnosis and Diagnostic Work Up .....	14
📖 Pathology.....	21
📖 Prognostic and Predictive Factors.....	32
📖 CEA in Non-Small Cell Lung Cancer .....	42
Patients and Methods .....	56
Results .....	60
Discussion .....	66
Conclusion.....	75
Summary .....	76
Recommendations .....	78
References .....	79
Arabic Summary	

## *List of Tables*

Table No.	Title	Page No.
<b>Table (1):</b>	2015 WHO classification of malignant epithelial tumors of lung.....	22
<b>Table (2):</b>	Summary statistics for baseline characteristics.....	61
<b>Table (3):</b>	The baseline levels of serum CEA and clinical characteristics of NSCLC patients .....	62
<b>Table (4):</b>	Frequency and percentage for the correlation between CEA level reduction and tumor response .....	64

## *List of Figures*

Fig. No.	Title	Page No.
<b>Figure (1):</b>	Globocal 2018 lung fact sheet: estimated number of new cases worldwide, all cancers, both sexes, all ages.....	4
<b>Figure (2):</b>	Globocal 2018 lung fact sheet: estimated number of deaths worldwide, all cancers, both sexes, all ages.....	5
<b>Figure (3):</b>	Age-standardized incidence rate per 100,000 among males and females. ....	6
<b>Figure (4):</b>	The nucleotide excision repair (NER) pathway,.....	36
<b>Figure (5):</b>	Ribonucleotide reductase messenger 1(RRM1). ....	38
<b>Figure (6):</b>	ROC curve for changes in CEA level as a predictor for tumor response. ....	63
<b>Figure (7):</b>	ROC curve for changes in CEA level in progressive disease. ....	65



## *List of Abbreviations*

<b>Abb.</b>	<b>Full term</b>
<i>AIS</i> .....	<i>Adenocarcinoma in situ</i>
<i>ALARA</i> .....	<i>As low as reasonable achieved</i>
<i>CA125</i> .....	<i>Cancer antigen 125</i>
<i>CEA</i> .....	<i>Carcinoembryonic antigen</i>
<i>CM</i> .....	<i>Conventional mediastinoscopy</i>
<i>CPS</i> .....	<i>Combined positive score</i>
<i>CR</i> .....	<i>Complete response</i>
<i>CT</i> .....	<i>Computed tomography</i>
<i>DFS</i> .....	<i>Disease free survival</i>
<i>DNA</i> .....	<i>Deoxyribonucleic acid</i>
<i>EBUS</i> .....	<i>Endobronchial ultrasound</i>
<i>ERCC1</i> .....	<i>Excision repair cross-complementation</i>
<i>IHC</i> .....	<i>Immunohistochemistry</i>
<i>IBR</i> .....	<i>Imaging based response</i>
<i>LDCT</i> .....	<i>Low dose computed tomography</i>
<i>MGS</i> .....	<i>Modified glasgow score</i>
<i>MIA</i> .....	<i>Minimally invasive adenocarcinoma</i>
<i>NER</i> .....	<i>Nucleotide excision repair</i>
<i>NLST</i> .....	<i>National lung screening trial</i>
<i>NOS</i> .....	<i>Not otherwise specified</i>
<i>NSCLC</i> .....	<i>Non-small cell lung cancer</i>
<i>NSE</i> .....	<i>Neuron-specific enolase</i>
<i>OR</i> .....	<i>Objective response</i>
<i>PD</i> .....	<i>Progressive disease</i>
<i>PD-1</i> .....	<i>Programmed death-1</i>
<i>PD-L1</i> .....	<i>Programmed death ligand 1</i>
<i>PR</i> .....	<i>Partial response</i>
<i>PSA</i> .....	<i>Prostate specific antigen</i>
<i>RECIST</i> .....	<i>Response evaluation criteria in solid tumor</i>

## *List of Abbreviations (Cont...)*

<b>Abb.</b>	<b>Full term</b>
<i>ROC</i> .....	<i>Receiver operator curve</i>
<i>RRM1</i> .....	<i>Ribonucleotide reductase messenger</i>
<i>RT-PCR</i> .....	<i>Reverse transcriptase polymerase chain reaction</i>
<i>SCC</i> .....	<i>Squamous cell carcinoma</i>
<i>SD</i> .....	<i>Stable disease</i>
<i>SHS</i> .....	<i>Second hand smoke</i>
<i>SLD</i> .....	<i>Sum of longest diameter</i>
<i>SPN</i> .....	<i>Solitary pulmonary nodules</i>
<i>SUV</i> .....	<i>Standardized uptake value</i>
<i>SVCO</i> .....	<i>Superior vena cava obstruction</i>
<i>TBNA</i> .....	<i>Transbronchial needle aspiration</i>
<i>TKIs</i> .....	<i>Tyrosine kinase inhibitors</i>
<i>TPS</i> .....	<i>Tumor proportion score</i>
<i>TTF-1</i> .....	<i>Thyroid transcription factor</i>
<i>TTNA</i> .....	<i>Transthoracic needle aspiration</i>
<i>UK</i> .....	<i>United Kingdom</i>
<i>VAM</i> .....	<i>Video-assisted mediastinoscopy</i>
<i>VATS</i> .....	<i>Video-assisted thoracoscopic surgery</i>
<i>WHO</i> .....	<i>World health organization</i>

## INTRODUCTION

Lung cancer represents the top cause of death and the most common cancer worldwide. In the United States, lung cancer is the second most common cancer accounts for 12.9% of new cancer diagnoses and 27.4 of all cancer deaths. Non small cell lung cancer (NSCLC) represents up to 80% of all lung cancers which divided into two major types: squamous cell carcinoma (SCC) and nonsquamous cell carcinoma (NSCC, including adenocarcinoma, large-cell carcinoma, and other subtypes) (*Meza et al., 2015*).

The ability to monitor response to treatment depend on imaging studies which is expensive and difficult as not all patients have measurable disease which complicate the availability of evaluating response so a number of biomarker had been used in diagnosis, prognosis and therapeutic monitoring (*Molina et al., 2009*).

CEA (carcinoembryonic antigen) is the most frequently used tumor marker in the world. It is a glycoprotein product of the gene *CEACAM-5*, produced in the fetal period by cells of the digestive tract and pancreas (*Hammarström, 1999*).

A number of tumor markers are used in monitoring response to treatment like PSA (prostate specific antigen) in prostate cancer and CA125 in ovarian cancer. CEA was



established as a prognostic factor in metastatic colon cancer and it is part of routine follow up as recommended by NCCN (*Benson et al., 2018*).

In the case of lung cancer, there is no sufficient sensitive and specific factor that could help in diagnosis and monitoring of response. A number of studies evaluate the role of CEA in diagnosis, prognosis and monitoring of response in lung cancer (*Yu et al., 2013*).